Related Experiment Video
Updated: Mar 23, 2026
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.9K
Quality cell therapy manufacturing by design
Yonatan Y Lipsitz1, Nicholas E Timmins2, Peter W Zandstra1,2,3,4
1Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada.
Nature Biotechnology
|April 8, 2016
Summary
Designing cell manufacturing processes using quality-by-design (QbD) principles can overcome challenges in producing cell-based therapies. QbD integration is key to reliable, cost-effective cell therapy manufacturing for future healthcare applications.
Area of Science:
- Biotechnology and Regenerative Medicine
- Pharmaceutical Manufacturing
- Cellular Therapeutics
Background:
- Cell-based therapies offer promising treatments for various diseases.
- Manufacturing challenges due to biological complexity hinder clinical translation.
- Current cell therapy production lacks standardization and cost-effectiveness.
Purpose of the Study:
- To advocate for the adoption of quality-by-design (QbD) principles in cell therapy manufacturing.
- To highlight the potential of QbD to address industrialization challenges in cell manufacturing.
- To emphasize the need for technology development to fully implement QbD.
Main Methods:
- Review of quality-by-design (QbD) principles and their application in biopharmaceutical manufacturing.
- Analysis of challenges in scaling up cell therapy production from laboratory to industrial levels.
- Identification of opportunities for integrating QbD into cell manufacturing processes.
Main Results:
- Quality-by-design (QbD) offers a framework for integrating scientific knowledge and risk management into process development.
- The biopharmaceutical industry is increasingly adopting QbD principles.
- Specific QbD applications in cell therapy manufacturing require further technological advancements.
Conclusions:
- Implementing quality-by-design (QbD) is essential for the reliable and cost-effective manufacturing of cell-based therapies.
- Linking measurable cell characteristics to product quality via QbD is critical for clinical success.
- Further research and development are needed to fully realize the potential of QbD in cell therapy manufacturing.
Related Concept Videos
01:27Upstream Processing
16
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
16
01:16Cell Lines
11.1K
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
11.1K